CampbellNRBurgessEChoiBCK. Methods and an overview of the Canadian recommendations. CMAJ1999;160(9 suppl):S1-S6.
2.
DaskalopoulouSSRabiDMZarnkeKB. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention and treatment of hypertension. Can J Cardiol. 2015;31(5):549-68.
3.
McAlisterFAWilkinsKJoffresM. Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ2011;183(9):1007-13.
4.
Chisholm-BurnsMAKim LeeJSpiveyCA. US pharmacists’ effect as team members on patient care: systematic review and meta-analyses. Med Care2010;48:923-33.
5.
SantschiVChioleroABurnandB. Impact of pharmacist care in the management of cardiovascular disease risk factors: s systematic review and meta-analysis of randomized trials. Arch Intern Med2011;171:1441-53.
6.
SantschiVChioleroAParadisG. Pharmacist interventions to improve cardiovascular disease risk factors in diabetes: a systematic review and metaanalysis of randomized controlled trials. Diabetes Care2012;35:2706-17.
7.
SantschiVChioleroAColosimoAL. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc2014;3:e000718.
8.
TsuyukiRHouleSCharroisT. A randomized trial of the effect of pharmacist prescribing on improving blood pressure in the community: the Alberta clinical trial in optimizing hypertension (RxACTION). Can Pharm J (Ott)2014;147:S18.
9.
PojskicNJacksonMMalekACiminoS.Impact of community pharmacist interventions in hypertension management on patient outcomes: a randomized controlled trial. Can Pharm J (Ott)2014;147:S17.
10.
HouleSKDTsuyukiRTCampbellNRC. The Canadian Hypertension Education Program (CHEP) 2011 Guidelines for Pharmacists. Can Pharm J (Ott)2011;144:295-304.
11.
HouleSKDPadwalRTsuyukiRT. The 2012-2013 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists: an update. Can Pharm J (Ott)2013;146:146-50.
12.
HouleSKDPadwalRPoirierLTsuyukiRT. The 2014 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists: an update. Can Pharm J (Ott)2014;147:203-8.
13.
MyersMGKaczorowskiJDawesMGodwinM.Automated office blood pressure measurement in primary care. Can Fam Phys2014;60:127-32.
14.
BeckettLGodwinM.The BpTRU automatic blood pressure monitor compared to 24 hour ambulatory blood pressure monitoring in the assessment of blood pressure in patients with hypertension. BMC Cardiovasc Disord2005;5:18.
15.
AndreadisEAAgaliotisGDAngelopoulosET. Automated office blood pressure and 24-h ambulatory measurements are equally associated with left ventricular mass index. Am J Hypertens2011;24:661-6.
16.
MuleGCaimiGCottoneS. Value of home blood pressures as predictor of target organ damage in mild arterial hypertension. J Cardiovasc Risk2002;9:123-9.
17.
OhkuboTKikuyaMMetokiH. Prognosis of “masked” hypertension and “white-coat” hypertension detected by 24-h ambulatory blood pressure monitoring: 10-year follow-up from the Ohasama Study. J Am Coll Cardiol2005;46:508-15.
18.
FranklinSSThijsLHansenTW. White-coat hypertension: new insights from recent studies. Hypertension2013;62:982-7.
19.
HanninenMRNiiranenTJPuukkaPJ. Determinants of masked hypertension in the general population: the Finn-Home study. J Hypertens2011;29:1880-8.
20.
AndalibAAkhtariSRigalR. Determinants of masked hypertension in hypertensive patients treated in a primary care setting. Intern Med J2012;42:260-6.
21.
BarochinerJCuffaroPEAparicioLS. Predictors of masked hypertension among treated hypertensive patients: an interesting association with orthostatic hypertension. Am J Hypertens2013;26:872-8.
22.
McAlisterFARobitailleCGillespieC. The impact of cardiovascular risk-factor profiles on blood pressure control rates in adults from Canada and the United States. Can J Cardiol2013;29:598-605.
23.
SteadLFBuitragoDPreciadoN. Physician advice for smoking cessation. Cochrane Database System Rev2013,(5):CD000165.
24.
CahillKStevensSPereraRLancasterT.Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database System Rev2013;(5):CD009329.
25.
JeeSHSuhIKimISAppelLJ.Smoking and atherosclerotic cardiovascular disease in men with low levels of serum cholesterol: the Korea Medical Insurance Corporation Study. JAMA1999;282:2149-55.
26.
NjolstadIArnesenELund-LarsenPG.Smoking, serum lipids, blood pressure and sex differences in myocardial infarction: a 12-year follow-up of the Finnmark Study. Circulation1996;93:450-6.
27.
PrescottEHippeMSchnohrP. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ1998;316:1043.
28.
YusufSHawkenSOunpuuS. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet2004;364:937-52.
29.
HuxleyRRWoodwardM.Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet2011;378:1297-305.
30.
QiaoQTervahautaMNissinenATuomilehtoJ.Mortality from all causes and from coronary heart disease related to smoking and changes in smoking during a 35-year follow-up of middle-aged Finnish men. Eur Heart J2000; 21:1621-6.
31.
SabaMDiepJSainiBDhippayomT.Meta-analysis of the effectiveness of smoking cessation interventions in community pharmacy. J Clin Pharm Ther2014;39:240-7.
